Formosa and AimMax Report Results of CPN-301 in the P-III Trial for the Treatment of Inflammation and Pain after Cataract Surgery
Shots:
- The P-III trial evaluates APP13007 vs PBO in a ratio (1:1) in 378 patients with inflammation and pain following cataract surgery
- The trial met 2 1EPs of producing rapid & sustained clearance of ocular inflammation and cure of ocular pain that was statistically & clinically superior, 26.5% vs 5.1% of patients showed sustained ACC count from POD8 through POD15, patients had ACC count on POD15 (58.6% vs 15.7%)
- Additionally, 68.0% vs 23% showed sustained ocular pain grade (pain-free) as early as POD4 through to POD15, 77.3% vs 43.7% were ocular pain-free at POD4, was well tolerated with a similar safety profile, no serious AEs were reported & showed comparable profiles of change in IOP from baseline
Ref: PRNewswire | Image: Formosa
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
